Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 0

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Association Between FDA Drug Recall Classification and Product-Related Characteristics

Bekele, Lantider K., Badar, M. Affan, Kluse, Christopher J.·2026·Therapeutic Innovation & Regulatory Science
DOI 10.1007/s43441-026-01016-9
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43441-026-01016-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 42

  1. Ghijs S, Wynendaele E, De Spiegeleer B. The continuing challenge of drug recalls: insights from a ten-year FDA data analysis. J Pharm Biomed Anal. 2024;249:116349. https://doi.org/10.1016/j.jpba.2024.116349. · doi:10.1016/j.jpba.2024.116349
  2. Mattingly AN, Mattingly TJ, Nguyen PAL, et al. Categorization and comparisons of drug recalls for manufacturers and compounders. J Am Pharm Assoc. 2022;62:1344–50. https://doi.org/10.1016/j.japh.2022.03.010. · doi:10.1016/j.japh.2022.03.010
  3. Nizam VPM, Yerram S, Patnam JD, et al. Ensuring product safety: a comprehensive retrospective study of USFDA drug recalls (2019–2023). J Pharm Innov. 2024;19:63. https://doi.org/10.1007/s12247-024-09869-z. · DOI · Paper page
  4. Wang B, Gagne JJ, Choudhry NK. The epidemiology of drug recalls in the United States. Arch Intern Med. 2012;172:1110–1. https://doi.org/10.1001/archinternmed.2012.2013. · DOI
  5. Hall K, Stewart T, Chang J, et al. Characteristics of FDA drug recalls: a 30-month analysis. Am J Health Syst Pharm. 2016;73:235–40. https://doi.org/10.2146/AJHP150277. · DOI
  6. Patel R, Vhora A, Jain D, et al. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023. Drug Discov Today. 2024;29:103993. https://doi.org/10.1016/j.drudis.2024.10399. · doi:10.1016/j.drudis.2024.10399
  7. Nagaich U, Sadhna D. Drug recall: an incubus for pharmaceutical companies and most serious drug recall of history. Int J Pharm Investig. 2015;5:13–9. https://doi.org/10.4103/2230-973X.147222. · DOI
  8. Chabalenge B, Jere E, Nanyangwe N, Hikaambo C, Mudenda S, Banda M, Kalungia A, Matafwali S. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems. J Med Access. 2022;6:1–13. https://doi.org/10.1177/27550834221141767. · DOI
  9. Fryze I, Naughton BD. Substandard and falsified medicine recalls in the legitimate supply chain: a systematic review of evidence. BMJ Open. 2025;15:e103672. https://doi.org/10.1136/bmjopen-2025-103672. · DOI · Paper page
  10. Barma S, Pathak N, Dhungana S, Jha PK, Shrestha S. Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal. Ther Adv Drug Saf. 2025;16:1–11. https://doi.org/10.1177/20420986251398725. · doi:10.1177/20420986251398725
  11. Lin ID, Hertig JB. Risk control drives risk assessment and risk review: a cause-and-effect model of pharmaceutical drug recall on patient safety. J Med Access. 2023;7:27550834231170075. https://doi.org/10.1177/27550834231170075. · doi:10.1177/27550834231170075
  12. Rumore MM. An analysis of Class I drug recalls, 1982–1996. Drug Inf J. 1998. https://doi.org/10.1177/009286159803200109. · doi:10.1177/009286159803200109
  13. Ebbers HC, Fuentes de Tienda N, Hoefnagel M, et al. Characterization of product recalls of biopharmaceuticals. Drug Discov Today. 2016;21(4):536–9. https://doi.org/10.1016/j.drudis.2015.10.020. · DOI
  14. Kerstiens EA, Byrn SR, Clase KL. Identification of quality risk factors for non-biological complex drugs and epilepsy drugs using statistical analysis of formulation-based recalls in the USA. AAPS PharmSciTech. 2022;23:19. https://doi.org/10.1208/s12249-021-02165-w. · doi:10.1208/s12249-021-02165-w
  15. Tirop LJ. Investigating pharmaceutical product recalls due discoloration: a Kenyan case review (January 2016–December 2024). J Pharm Policy Pract. 2025;18(1):2522314. https://doi.org/10.1080/20523211.2025.2522314. · doi:10.1080/20523211.2025.2522314
  16. AlQuadeib BT, Alfagih IM, Alnahdi AH, et al. Medicine recalls in Saudi Arabia: a retrospective review of drug alerts (2010–2019). Future J Pharm Sci. 2020;6:91. https://doi.org/10.1186/s43094-020-00112-3. · doi:10.1186/s43094-020-00112-3
  17. Almutairi M, et al. Human medicines recall announcements in Saudi Arabia (2017–2022). Ther Innov Regul Sci. 2024;58:689–95. https://doi.org/10.1007/s43441-024-00635-4. · doi:10.1007/s43441-024-00635-4
  18. Oliveira CLCG, Machado VF, Tavares HF, et al. Recall of substandard medicines in Brazil during the period 2010–2018. BMC Health Serv Res. 2023;23:238. https://doi.org/10.1186/s12913-023-09225-w. · DOI
  19. Berrido AM, Byrd JB. Angiotensin receptor blockers and the risk of cancer: insights from clinical trials and recent drug recalls. Curr Hypertens Rep. 2020;22:20. https://doi.org/10.1007/s11906-020-1021-0. · DOI
  20. Devine M, et al. A retrospective cohort study of the 2018 angiotensin receptor blocker recalls and subsequent drug shortages in patients with hypertension. J Am Heart Assoc. 2024;13:e032266. https://doi.org/10.1161/JAHA.123.03226. · doi:10.1161/jaha.123.03226
  21. Yerram S, Nizam VPM, Srivastava S, Nanduri S. Nitrosamine contamination in pharmaceuticals: a retrospective regulatory analysis (2018–2025). Ther Innov Regul Sci. 2025. https://doi.org/10.1007/s43441-025-00891-y. · doi:10.1007/s43441-025-00891-y
  22. Bharate SS. Critical analysis of drug product recalls due to nitrosamine impurities. J Med Chem. 2021;64:2923–36. https://doi.org/10.1021/acs.jmedchem.0c02120. · doi:10.1021/acs.jmedchem.0c02120
  23. Kim M, Noh KB. Board diversity and the timing of drug recalls: implications for public health. Finance Res Lett. 2025;80:107387. https://doi.org/10.1016/j.frl.2025.107387. · doi:10.1016/j.frl.2025.107387
  24. Zhou Y. The effects of lobbying on the FDA’s recall classification. BMC Med Ethics. 2023;24:41. https://doi.org/10.1186/s12910-023-00921-0. · doi:10.1186/s12910-023-00921-0
  25. Annema PA, Nahar-van Venrooij LMW, Bouvy ML, et al. Patient perspectives on drug recalls in the Netherlands. Int J Clin Pharm. 2026. https://doi.org/10.1007/s11096-025-02082-z. · DOI
  26. Devine JW, Tadrous M, Hernandez I, Mukhopadhyay N, Rothenberger SD, Callaway Kim K, Gellad WF, Suda KJ. Effects of the valsartan recall on heart failure patients: a nationwide analysis. Pharmacoepidemiol Drug Saf. 2024;33:e5777. https://doi.org/10.1002/pds.5777. · DOI
  27. O’Malley P. Drug recalls and significance for safe clinical nurse specialist prescribing. Clin Nurse Specialist. 2021;35(6):288–90. https://doi.org/10.1097/nur.0000000000000628. · doi:10.1097/nur.0000000000000628
  28. Azghandi M, et al. Minimization of drug shortages in pharmaceutical supply chains: a simulation-based analysis of Drug Recall Patterns And Inventory Policies. Complexity. 2018. https://doi.org/10.1155/2018/6348413. · DOI
  29. McHugh ML. The Chi-square Test of Independence. Biochem Med (Zagreb). 2013;23:143–9. https://doi.org/10.11613/BM.2013.018. · DOI · Paper page
  30. Ferdous SF, Badar MA, Javaid M. Impact of COVID-19 on engineering and technology course outcomes. Proceedings of the 2021 ASEE Annual Conference & Exposition; July 26–29, 2021; Virtual Conference. 11 p. Available at: https://peer.asee.org/37277
  31. Akoglu H. User’s guide to correlation coefficients. Turk J Emerg Med. 2018;18(3):91–3. https://doi.org/10.1016/j.tjem.2018.08.001. · DOI · Paper page
  32. Bhattacharya A, Kang PC. Retrospective analysis of U.S. Food and Drug Administration recalls of artificial tear solutions from 2014 to 2025. J Cataract Refract Surg. 2026;52(4):373–8. https://doi.org/10.1097/j.jcrs.0000000000001835. · doi:10.1097/j.jcrs.0000000000001835
  33. Hussong D. Sterile products: advances and challenges in formulation, manufacturing, and regulatory aspects—a regulatory review perspective. AAPS PharmSciTech. 2010;11:1482–4. https://doi.org/10.1208/s12249-010-9503-z. · doi:10.1208/s12249-010-9503-z
  34. Livingston AN, Mattingly TJ. Drug and medical device product failures and the stability of the pharmaceutical supply chain. J Am Pharm Assoc. 2021;61:e119–22. https://doi.org/10.1016/j.japh.2020.07.005. · doi:10.1016/j.japh.2020.07.005
  35. Buschmann H, Handler N, Holzgrabe U. The quality of drugs and drug products – always guaranteed? J Pharm Biomed Anal. 2024;239:115880. https://doi.org/10.1016/j.jpba.2023.115880. · DOI
  36. Jimenez L. Microbial landscape of pharmaceutical failures: a 21-year review of FDA enforcement reports. BioTech. 2026;15(1):8. https://doi.org/10.3390/biotech15010008. · doi:10.3390/biotech15010008
  37. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69(3):295–307. https://doi.org/10.1007/s00228-012-1353-z. · DOI · Paper page
  38. Opuni KFM, Kretchy JP, Agyabeng K, et al. Contamination of herbal medicinal products in low- and middle-income countries: a systematic review. Heliyon. 2023;9(9):e19370. https://doi.org/10.1016/j.heliyon.2023.e19370. · DOI
  39. Pisani E, Nistor AL, Hasnida A, Parmaksiz K, Xu J, Kok MO. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome Open Res. 2019;4:70. https://doi.org/10.12688/wellcomeopenres.15236.1. · DOI
  40. Wickett E, Plumlee M, Smilowitz K, Phanouvong S, Pribluda V. Inferring sources of substandard and falsified products in pharmaceutical supply chains. IISE Trans. 2023;56(3):241–56. https://doi.org/10.1080/24725854.2023.2174277. · doi:10.1080/24725854.2023.2174277
  41. Newton PN, Bond KC, Oxford Statement signatories. Global access to quality-assured medical products: the Oxford Statement and call to action. Lancet Glob Health. 2019;7(12):e1609–11. https://doi.org/10.1016/s2214-109x(19)30426-7. · doi:10.1016/s2214-109x(19)30426-7
  42. Bekele LK, Kluse CJ, Badar MA. Data-driven insights from FDA inspections for pharmaceutical quality management system improvement. J Pharm Innov. 2026;21:373. https://doi.org/10.1007/s12247-026-10611-0. · doi:10.1007/s12247-026-10611-0

Metadata

Authors
Bekele, L. K., Badar, M. A., & Kluse, C. J.
Venue
Therapeutic Innovation & Regulatory Science
Publisher
Springer Science and Business Media LLC
Published
2026-07-11
Volume
60
Issue
6
Pages
1697-1709
ISSN
  • 2168-4790
  • 2168-4804
DOI
10.1007/s43441-026-01016-9
Cited by
0
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association Between FDA Drug Recall Classification and Product-Related Characteristics. https://app.cochat.ai/papers/10.1007/s43441-026-01016-9
The paper
Bekele, L. K., Badar, M. A., & Kluse, C. J. (2026). Association Between FDA Drug Recall Classification and Product-Related Characteristics. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01016-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.